These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 1512912)

  • 1. Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval.
    Powe NR; Griffiths RI; de Lissovoy G; Anderson GF; Watson AJ; Greer JW; Herbert RJ; Eggers PW; Milam RA; Whelton PK
    JAMA; 1992 Sep; 268(11):1434-40. PubMed ID: 1512912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states.
    Thamer M; Richard C; Ray NF; Greer JW; Cotter DJ; Pearson BC
    Am J Kidney Dis; 1996 Aug; 28(2):235-49. PubMed ID: 8768919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients.
    Powe NR; Griffiths RI; Anderson GF; de Lissovoy G; Watson AJ; Greer JW; Herbert RJ; Whelton PK
    Am J Kidney Dis; 1993 Oct; 22(4):557-67. PubMed ID: 8213796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990-1996.
    Cotter DJ; Thamer M; Kimmel PL; Sadler JH
    Kidney Int; 1998 Dec; 54(6):2129-39. PubMed ID: 9853279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the first year of Medicare coverage of erythropoietin.
    Griffiths RI; Powe NR; Greer J; de Lissovoy G; Anderson GF; Whelton PK; Watson AJ; Eggers PW
    Health Care Financ Rev; 1994; 15(3):83-102. PubMed ID: 10137799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in anemia at initiation of dialysis in the United States.
    Obrador GT; Roberts T; St Peter WL; Frazier E; Pereira BJ; Collins AJ
    Kidney Int; 2001 Nov; 60(5):1875-84. PubMed ID: 11703606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients.
    Powe NR; Griffiths RI; Watson AJ; Anderson GF; de Lissovoy G; Greer JW; Herbert RJ; Milam RA; Whelton PK
    J Am Soc Nephrol; 1994 Jan; 4(7):1455-65. PubMed ID: 8161727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of race on access to recombinant human erythropoietin in long-term hemodialysis patients.
    Petronis KR; Carroll CE; Held PJ; Port FK
    JAMA; 1994 Jun; 271(22):1760-3. PubMed ID: 8196119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.
    Thamer M; Zhang Y; Kaufman J; Cotter D; Dong F; Hernán MA
    JAMA; 2007 Apr; 297(15):1667-74. PubMed ID: 17440144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time.
    Lu WX; Jones-Burton C; Zhan M; Salzberg DJ; Moore J; Fink JC
    Nephron Clin Pract; 2005; 101(2):c79-86. PubMed ID: 15976508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin.
    Takeda A; Toda T; Shinohara S; Mogi Y; Matsui N
    Am J Kidney Dis; 2002 Jul; 40(1):104-9. PubMed ID: 12087567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. For-profit versus not-for-profit dialysis care for children with end stage renal disease.
    Furth SL; Hwang W; Neu AM; Fivush BA; Powe NR
    Pediatrics; 1999 Sep; 104(3 Pt 1):519-24. PubMed ID: 10469779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racial differences in choice of dialysis modality for children with end-stage renal disease.
    Furth SL; Powe NR; Hwang W; Neu AM; Fivush BA
    Pediatrics; 1997 Apr; 99(4):E6. PubMed ID: 9099781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EPO adjustments in patients with elevated hemoglobin levels: provider practice patterns compared with recommended practice guidelines.
    Collins AJ; Ebben JP; Gilbertson DT
    Am J Kidney Dis; 2007 Jan; 49(1):135-42. PubMed ID: 17185154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of pure red cell aplasia in US dialysis patients: the limits of the Medicare data.
    Collins AJ; Li S; Adamson JW; Gilbertson DT
    Am J Kidney Dis; 2004 Mar; 43(3):464-70. PubMed ID: 14981604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients.
    Shih YC; Guo A; Just PM; Mujais S
    Kidney Int; 2005 Jul; 68(1):319-29. PubMed ID: 15954923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [REIN Report 2011--summary].
    Couchoud C; Lassalle M; Jacquelinet C
    Nephrol Ther; 2013 Sep; 9 Suppl 1():S3-6. PubMed ID: 24119584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities.
    House AA; Pham B; Pagé DE
    Nephrol Dial Transplant; 1998 Jul; 13(7):1763-9. PubMed ID: 9681725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A; McCrea JB
    ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.